PWM
TSHA icon

Palumbo Wealth Management’s Taysha Gene Therapies TSHA Stock Holding History

Palumbo Wealth Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Buy
149,173
+2,464
+2% +$14.6K 0.21% 78
2026
Q1 		$656K Sell
146,709
-31,298
-18% -$146K 0.16% 99
2025
Q4 		$979K Buy
178,007
+20,654
+13% +$100K 0.24% 79
2025
Q3 		$515K Buy
+157,353
New +$446K 0.16% 87

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Palumbo Wealth Management's TSHA Position: Q2 2026 in Review

Palumbo Wealth Management increased its Taysha Gene Therapies (TSHA) stake by 1.7% in Q2 2026, buying an estimated $14.6K and bringing the position to 149,173 shares worth $1.02M. The position accounts for 0.21% of the portfolio, ranked #78.

Palumbo Wealth Management first reported a position in TSHA in Q3 2025 and has held it in 4 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Palumbo Wealth Management held 149,173 shares of Taysha Gene Therapies worth $1.02M as of Q2 2026.
  • Palumbo Wealth Management bought 2,464 Taysha Gene Therapies shares in Q2 2026, an estimated $14.6K.
  • Taysha Gene Therapies made up 0.21% of Palumbo Wealth Management's portfolio in Q2 2026, its #78 holding.
  • Palumbo Wealth Management first reported a position in Taysha Gene Therapies in Q3 2025 and has held it in 4 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Palumbo Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.